Open Access

RNA interference-mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells

  • Authors:
    • Tao Liu
    • Yixiang Liao
    • Huangheng Tao
    • Jinmin Zeng
    • Gang Wang
    • Zhonghua Yang
    • Yongzhi Wang
    • Yu Xiao
    • Jiajie Zhou
    • Xinghuan Wang
  • View Affiliations

  • Published online on: January 24, 2018     https://doi.org/10.3892/ol.2018.7847
  • Pages: 4129-4136
  • Copyright : © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Several studies have shown that transient receptor potential cation channel subfamily M member 8 (TRPM8), which has been regarded as a novel prostate‑specific marker, serves a key role in processes such as the proliferation, viability and cell migration of prostate cancer cells. Efforts have been made to uncover the potential role of targeting TRPM8 in the management of prostate cancer; it has been verified that TRPM8‑targeted blockade, either by RNA interference-mediated depletion or specific TRPM8 inhibitors, could reduce the rate of proliferation and proliferative fraction, and induce apoptosis in prostate cancer cells. The aim of the present study was to investigate the effect of knockdown of TRPM8 on chemosensitivity in prostate cancer LNCaP and PC3 cells. The RNA interference‑mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen‑activated protein kinase (hereafter p38) and c‑Jun N‑terminal kinase (JNK)/mitogen‑activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK. The results demonstrate that the targeted silencing of TRPM8 expression is a therapeutic strategy for treatment of prostate cancer that has considerable potential, even for castration‑resistant prostate cancer.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Zhang L and Barritt GJ: Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells. Cancer Res. 64:8365–8373. 2004. View Article : Google Scholar : PubMed/NCBI

3 

Egan A, Dong Y, Zhang H, Qi Y, Balk SP and Sartor O: Castration-resistant prostate cancer: Adaptive responses in the androgen axis. Cancer Treat Rev. 40:426–433. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Katzenwadel A and Wolf P: Androgen deprivation of prostate cancer: Leading to a therapeutic dead end. Cancer Lett. 367:12–17. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, De Rubertis G, Barbanti G, Bianco V, Brozzetti S and Francini E: Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: A single-institution experience. Med Oncol. 32:522015. View Article : Google Scholar : PubMed/NCBI

6 

Thebault S, Flourakis M, Vanoverberghe K, Vandermoere F, Roudbaraki M, Lehen'kyi V, Slomianny C, Beck B, Mariot P, Bonnal JL, et al: Differential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res. 66:2038–2047. 2006. View Article : Google Scholar : PubMed/NCBI

7 

Yee NS: Roles of TRPM8 ion channels in cancer: Proliferation, survival and invasion. Cancers (Basel). 7:2134–2146. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Grolez GP and Gkika D: TRPM8 puts the chill on prostate cancer. Pharmaceuticals (Basel). 9:E442016. View Article : Google Scholar : PubMed/NCBI

9 

Flourakis M and Prevarskaya N: Insights into Ca2+ homeostasis of advanced prostate cancer cells. Biochim Biophys Acta. 1793:1105–1109. 2009. View Article : Google Scholar : PubMed/NCBI

10 

Vanoverberghe K, Vanden Abeele F, Mariot P, Lepage G, Roudbaraki M, Bonnal JL, Mauroy B, Shuba Y, Skryma R and Prevarskaya N: Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ. 11:321–330. 2004. View Article : Google Scholar : PubMed/NCBI

11 

Skryma R, Mariot P, Bourhis XL, Coppenolle FV, Shuba Y, Vanden Abeele F, Legrand G, Humez S, Boilly B and Prevarskaya N: Store depletion and store-operated Ca2+ current in human prostate cancer LNCaP cells: Involvement in apoptosis. J Physiol. 527:71–83. 2000. View Article : Google Scholar : PubMed/NCBI

12 

Vanden AF, Roudbaraki M, Shuba Y, Skryma R and Prevarskaya N: Store-operated Ca2+ current in prostate cancer epithelial cells. Role of endogenous Ca2+ transporter type 1. J Biol Chem. 278:15381–15389. 2003. View Article : Google Scholar : PubMed/NCBI

13 

Yu S, Xu Z, Zou C, Wu D, Wang Y, Yao X, Ng CF and Chan FL: Ion channel TRPM8 promotes hypoxic growth of prostate cancer cells via an O2-independent and RACK1-mediated mechanism of HIF-1α stabilization. J Pathol. 234:514–525. 2014. View Article : Google Scholar : PubMed/NCBI

14 

Peng M, Wang Z, Yang Z, Tao L, Liu Q, Yi LU and Wang X: Overexpression of short TRPM8 variant alpha promotes cell migration and invasion and decreases starvation-induced apoptosis in prostate cancer LNCaP cells. Oncol Lett. 10:1378–1384. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Bidaux G, Borowiec AS, Dubois C, Delcourt P, Schulz C, Vanden Abeele F, Lepage G, Desruelles E, Bokhobza A, Dewailly E, et al: Targeting of short TRPM8 isoforms induces 4TM-TRPM8-dependent apoptosis in prostate cancer cells. Oncotarget. 7:29063–29080. 2016. View Article : Google Scholar : PubMed/NCBI

16 

Asuthkar S, Velpula KK, Elustondo PA, Demirkhanyan L and Zakharian E: TRPM8 channel as a novel molecular target in androgen-regulated prostate cancer cells. Oncotarget. 6:17221–17236. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Valero ML, Mello de Queiroz F, Stühmer W, Viana F and Pardo LA: TRPM8 ion channels differentially modulate proliferation and cell cycle distribution of normal and cancer prostate cells. PLoS One. 7:e518252012. View Article : Google Scholar : PubMed/NCBI

18 

Grolez GP and Gkika D: TRPM8 puts the chill on prostate cancer. Pharmaceuticals (Basel). 9:E442016. View Article : Google Scholar : PubMed/NCBI

19 

Zhu G, Wang X, Yang Z, Cao H, Meng Z, Wang Y and Chen D: Effects of TRPM8 on the proliferation and angiogenesis of prostate cancer PC-3 cells in vivo. Oncol Lett. 2:1213–1217. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Yang ZH, Wang XH, Wang HP and Hu LQ: Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells. Asian J Androl. 11:157–165. 2009. View Article : Google Scholar : PubMed/NCBI

21 

Peng M, Wang Z, Yang Z, Tao L, Liu Q, Yi LU and Wang X: Overexpression of short TRPM8 variant α promotes cell migration and invasion and decreases starvation-induced apoptosis in prostate cancer LNCaP cells. Oncol Lett. 10:1378–1384. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Valero M, Morenilla-Palao C, Belmonte C and Viana F: Pharmacological and functional properties of TRPM8 channels in prostate tumor cells. Pflugers Arch. 461:99–114. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Liu T, Fang Z, Wang G, Shi M, Wang X, Jiang K, Yang Z, Cao R, Tao H, Wang X and Zhou J: Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells. Oncol Lett. 11:182–188. 2016. View Article : Google Scholar : PubMed/NCBI

24 

Petrioli R, Pascucci A, Conca R, Chiriacò G, Francini E, Bargagli G, Fiaschi AI, Manganelli A, De Rubertis G and Barbanti G: Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: A randomised phase II study. Br J Cancer. 104:613–619. 2011. View Article : Google Scholar : PubMed/NCBI

25 

Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, et al: Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 63:4196–4203. 2003.PubMed/NCBI

26 

Bidaux G, Flourakis M, Thebault S, Zholos A, Beck B, Gkika D, Roudbaraki M, Bonnal JL, Mauroy B, Shuba Y, et al: Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function. J Clin Invest. 117:1647–1657. 2007. View Article : Google Scholar : PubMed/NCBI

27 

Thebault S, Lemonnier L, Bidaux G, Flourakis M, Bavencoffe A, Gordienko D, Roudbaraki M, Delcourt P, Panchin Y, Shuba Y, et al: Novel role of cold/menthol-sensitive transient receptor potential melastatine family member 8 (TRPM8) in the activation of store-operated channels in LNCaP human prostate cancer epithelial cells. J Biol Chem. 280:39423–39435. 2005. View Article : Google Scholar : PubMed/NCBI

28 

Kim SH, Nam JH, Park EJ, Kim BJ, Kim SJ, So I and Jeon JH: Menthol regulates TRPM8-independent processes in PC-3 prostate cancer cells. Biochim Biophys Acta. 1792:33–38. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, T., Liao, Y., Tao, H., Zeng, J., Wang, G., Yang, Z. ... Wang, X. (2018). RNA interference-mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells. Oncology Letters, 15, 4129-4136. https://doi.org/10.3892/ol.2018.7847
MLA
Liu, T., Liao, Y., Tao, H., Zeng, J., Wang, G., Yang, Z., Wang, Y., Xiao, Y., Zhou, J., Wang, X."RNA interference-mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells". Oncology Letters 15.4 (2018): 4129-4136.
Chicago
Liu, T., Liao, Y., Tao, H., Zeng, J., Wang, G., Yang, Z., Wang, Y., Xiao, Y., Zhou, J., Wang, X."RNA interference-mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells". Oncology Letters 15, no. 4 (2018): 4129-4136. https://doi.org/10.3892/ol.2018.7847